⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRBP News
Corbus Pharmaceuticals Holdings, Inc.
Form 8-K
sec.gov
CRBP
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
globenewswire.com
CRBP
Form 8-K
sec.gov
CRBP
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
globenewswire.com
CRBP
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report USA - English India - English
prnewswire.com
CLVT
LLY
GSK
JNJ
SNY
CELC
CRBP
BMY
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
CRBP
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration
businesswire.com
V
CRBP
LEAD
GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among Others - ResearchAndMarkets.com
businesswire.com
TECH
PEP
CGNX
LZ
AKRO
CRBP
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
globenewswire.com
CRBP
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
globenewswire.com
CRBP